       Document 0753
 DOCN  M9640753
 TI    Will preventive HIV vaccine efficacy trials be possible with female
       injection drug users?
 DT    9604
 AU    Meyers K; Metzger DS; McLellan AT; Navaline H; Sheon AR; Woody GE;
       University of Pennsylvania/Philadelphia Veterans Medical Center,; Center
       for Studies of Addiction, USA.
 SO    J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 15;10(5):577-85.
       Unique Identifier : AIDSLINE MED/96142221
 AB    This article examines whether preventive HIV vaccines trials will be
       viable among female injection drug users (IDUs). Of the 137 women who
       completed baseline serologic and behavioral assessments, 121 (88%) were
       seronegative; all enrolled in Project Jumpstart in Philadelphia (PA,
       U.S.A.), a vaccine preparedness initiative cosponsored by NIAID and
       NIDA. Subjects were seen every 3 months for risk and vaccine opinion
       assessment, risk reduction counseling, and HIV antibody testing. The
       baseline prevalence rate of HIV infection was 12% (16 of 137) with an
       annual incidence rate of 3.5% (4 of 114) during the first year. Of the
       121 baseline seronegative women, 28% shared needles and 52% engaged in
       unprotected intercourse. Sixty percent of the baseline seronegative
       women reported being willing to be one of the first people to try an HIV
       vaccine. According to logistic regression, needle sharers were 12.8
       times more likely, women who engaged in sex for drugs or money 6.6 times
       more likely, out-of-treatment women 3.5 times more likely, and those who
       believed that vaccines can prevent disease acquisition 3 times more
       likely to report willingness to try an HIV vaccine than their respective
       counterparts. At 1-year postbaseline assessment, 98% of the women had
       behavioral data collected and 95% had serologic specimens collected.
       Given that seroconversions occur and that these women engage in risk
       behaviors, report willingness to try an HIV vaccine, and can be retained
       for longitudinal assessment, they appear to be suitable participants for
       preventive HIV vaccine efficacy trials. Nonetheless, work is required to
       insure that these women make informed and knowledgeable decisions
       regarding trial enrollment.
 DE    Adult  Aged  AIDS Vaccines/*ADMINISTRATION & DOSAGE  Clinical
       Trials/*STATISTICS & NUMER DATA  Cohort Studies  Female  Human  HIV
       Antibodies/ANALYSIS  HIV Infections/EPIDEMIOLOGY/IMMUNOLOGY/*PREVENTION
       & CONTROL  HIV Seroprevalence/TRENDS  *HIV-1  Incidence  Male  Middle
       Age  Patient Compliance  Philadelphia/EPIDEMIOLOGY  Prevalence
       Risk-Taking  Substance Abuse, Intravenous/*COMPLICATIONS/PSYCHOLOGY
       Support, U.S. Gov't, P.H.S.  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

